NICE Backs Hep C Drug Zepatier After Merck Offers Price Discount

UK HTA gives provisional backing to Merck’s once-daily fixed-dose hepatitis C combo Zepatier after the US drug maker offers an undisclosed price cut.

Hepatitis C

The National Institute for Health and Care Excellence (NICE) has provisionally okayed use of Merck & Co. Inc.’s Zepatier (elbasvir and grazoprevir) as a treatment for adults with chronic hepatitis C virus genotypes 1 or 4 infection, with or without ribavirin, on Britain’s publicly funded National Health Service (NHS).

More from Anti-infective

In Brief: DIOSynVax And ACM Biolabs To Develop Bird Flu Vaccine

 

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.

GSK’s Blujepa Brings Innovation To The Antibiotic Space

 

The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.

Profile: Anil Koul’s Journey From ‘Jumping Genes’ To Sirturo And AI-Led Drug Discovery

 

Professor Anil Koul shares vignettes of his life and career trajectory, a captivating mix of hope, science and destiny that took him to the lab of eminent cancer biologist Alex Ullrich at the Max Planck Institute and also saw him contribute to the development of breakthrough TB drug bedaquiline. He also talks about Medicine 3.0 and the intersection of science and spirituality.

Merck’s HIV Combo Shows Non-Inferiority To Gilead’s Biktarvy

 

The company is developing doravirine and islatravir together as an alternative to therapies containing integrase inhibitors, like Biktarvy, especially as HIV patients age.

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By 

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.